drugset / Trial / NCT00838279

Lamotrigine 25 mg Chewable Tablets, Fasting

NCT00838279

Phase 1 Completed 32 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to compare the rate and extent of absorption of lamotrigine 25 mg chewable dispersible tablets (test) versus Lamictal® (reference) administered as 2 x 25 mg chewable dispersible tablets under fasting conditions.

Timeline

Start
2002-02
Primary completion
2002-03
Completion
2002-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamotrigine Small molecule 25 mg

Indications

No indication recorded.